Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial

Takanori Teshima, Yasushi Onishi, Koji Kato, Shuichi Taniguchi, Koichi Miyamura, Kentaro Fukushima, Jun Kato, Takayuki Ishikawa, Noriko Doki, Hirohisa Nakamae, Yoshinobu Maeda, Yoshihiro Inamoto, Masaya Okada, Akio Maki, Fumika Shimada, Takeshi Tajima, Monika Wroclawska, Robert Zeiser, Makoto Onizuka

Open source

DOI: 10.1007/s12185-024-03772-6
Published: 2024-05-25
Container: International Journal of Hematology
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s12185-024-03772-6,
  title = {Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial},
  author = {Takanori Teshima and Yasushi Onishi and Koji Kato and Shuichi Taniguchi and Koichi Miyamura and Kentaro Fukushima and Jun Kato and Takayuki Ishikawa and Noriko Doki and Hirohisa Nakamae and Yoshinobu Maeda and Yoshihiro Inamoto and Masaya Okada and Akio Maki and Fumika Shimada and Takeshi Tajima and Monika Wroclawska and Robert Zeiser and Makoto Onizuka},
  year = {2024},
  journal = {International Journal of Hematology},
  doi = {10.1007/s12185-024-03772-6},
  url = {https://doi.org/10.1007/s12185-024-03772-6}
}

RIS

TY  - JOUR
TI  - Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
AU  - Takanori Teshima
AU  - Yasushi Onishi
AU  - Koji Kato
AU  - Shuichi Taniguchi
AU  - Koichi Miyamura
AU  - Kentaro Fukushima
AU  - Jun Kato
AU  - Takayuki Ishikawa
AU  - Noriko Doki
AU  - Hirohisa Nakamae
AU  - Yoshinobu Maeda
AU  - Yoshihiro Inamoto
AU  - Masaya Okada
AU  - Akio Maki
AU  - Fumika Shimada
AU  - Takeshi Tajima
AU  - Monika Wroclawska
AU  - Robert Zeiser
AU  - Makoto Onizuka
PY  - 2024
JO  - International Journal of Hematology
DO  - 10.1007/s12185-024-03772-6
UR  - https://doi.org/10.1007/s12185-024-03772-6
ER  -

APA

Teshima, T., Onishi, Y., Kato, K., Taniguchi, S., Miyamura, K., Fukushima, K., Kato, J., Ishikawa, T., Doki, N., Nakamae, H., Maeda, Y., Inamoto, Y., Okada, M., Maki, A., Shimada, F., Tajima, T., Wroclawska, M., Zeiser, R., & Onizuka, M. (2024). Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03772-6

Source records

crossref · retrieved 2026-09-26T00:14:51.570Z